The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech ...

The clearance of Redemplo for a rare genetic disorder marks Arrowhead’s transition, after two decades, into a ...

Analysts say the two new indications should help Eylea HD as Regeneron battles for market share with Roche’s Vabysmo.

The deal gives J&J access to a pipeline of drugs designed to “hold and kill” tumors, led by a prostate cancer medicine that’s ...

Pyrukynd, which Agios sells for a rare type of anemia, missed one of its main objectives in a study seen as crucial for its ...

The purchase would give Abbott access to cancer screening tests including Cologuard and blood tests for multi-cancer early ...

Shares of Contineum Therapeutics dipped by the double-digits late Thursday after investors learned of a clinical setback for ...

As Anaptysbio seeks to split off a royalty business, both companies claim the other breached contracts surrounding ...

The cell therapy maker said Thursday the raise will support an ongoing trial of its experimental treatment for the ...

Artios Pharma, which looking for newer targets that, like PARP inhibitors, affect the way tumors fix themselves, said its ...

Roche claimed the results make its drug giredestrant the first of its kind, a so-called oral SERD, to show a benefit in the ...

Winrevair, which Merck has identified as a “growth driver,” significantly improved blood flow through the lungs to the heart ...